Loading
A phase 3 trial of Tiragolumab, Atezolizumab, Carboplatin and Etoposide in small-cell lung cancer, run by Hoffmann-La Roche, now completed.
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT04665856 by Hoffmann-La Roche, with 123 participants enrolled, started 2020-12-21 and reached its primary completion in 2023-08-31. Interventions recorded: Tiragolumab, Atezolizumab, Carboplatin, Etoposide and Tiragolumab Matching Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
123 enrolled.
95% CI 4.30 to 6.77; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication · 95% CI 4.53 to 7.89
Source95% CI 10.35 to 22.44; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication · 95% CI 14.26 to 20.86
Source95% CI 45.01 to 71.63; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication · 95% CI 68.13 to 90.30
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)primary | Placebo + Atezolizumab + Carboplatin + Etoposide | 56 | 5.39 months | 0.65 (0.43 to 0.97) | 0.0348 | link |
| Tiragolumab + Atezolizumab + Carboplatin + Etoposide | 54 | 5.59 months | ||||
| Overall Survival (OS) in the PASprimary | Placebo + Atezolizumab + Carboplatin + Etoposide | 56 | 13.54 months | 0.89 (0.56 to 1.4) | 0.6105 | link |
| Tiragolumab + Atezolizumab + Carboplatin + Etoposide | 54 | 18.69 months | ||||
| Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS | Placebo + Atezolizumab + Carboplatin + Etoposide | 56 | 58.9% | - | 0.0136 | link |
| Tiragolumab + Atezolizumab + Carboplatin + Etoposide | 54 | 81.5% |
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares TIGIT blockade, Tiragolumab, Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Small-cell lung cancer and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.